Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials

Trial Profile

An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs Voxergolide (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Registrational
  • Acronyms 03OLE
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Jun 2018 Status changed from planning to recruiting.
    • 19 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top